<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677530</url>
  </required_header>
  <id_info>
    <org_study_id>CR108942</org_study_id>
    <secondary_id>40411813EDI1011</secondary_id>
    <nct_id>NCT04677530</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-40411813 in Healthy Japanese Male Participants</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose and Multiple Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-40411813 in Healthy Japanese Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)&#xD;
      after single dose and multiple dose administrations of JNJ-40411813 in Japanese healthy adult&#xD;
      male participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Actual">May 21, 2021</completion_date>
  <primary_completion_date type="Actual">May 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Plasma Concentration of JNJ-40411813</measure>
    <time_frame>Predose, up to 96 hours postdose (Day 5)</time_frame>
    <description>Plasma samples will be analyzed to determine concentrations of JNJ-40411813 using a validated, specific, and sensitive liquid chromatography mass spectrometry/mass spectrometry (LC-MS/MS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Plasma Concentration of JNJ-40411813</measure>
    <time_frame>Predose, up to 312 hours postdose (Day 14)</time_frame>
    <description>Plasma samples will be analyzed to determine concentrations of JNJ-40411813 using a validated, specific, and sensitive LC-MS/MS.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: JNJ-40411813 or Matching Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of JNJ-40411813 or a matching placebo in Cohorts 1, 2, and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: JNJ-40411813</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of JNJ-40411813 in Cohort 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: JNJ-40411813 or Matching Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a multiple oral dose of JNJ-40411813 or a matching placebo in Cohort 5 and optional Cohort 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-40411813</intervention_name>
    <description>JNJ-40411813 will be administered orally.</description>
    <arm_group_label>Part 1: JNJ-40411813 or Matching Placebo</arm_group_label>
    <arm_group_label>Part 2: JNJ-40411813</arm_group_label>
    <arm_group_label>Part 3: JNJ-40411813 or Matching Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Matching placebo will be administered orally.</description>
    <arm_group_label>Part 1: JNJ-40411813 or Matching Placebo</arm_group_label>
    <arm_group_label>Part 3: JNJ-40411813 or Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be a Japanese man&#xD;
&#xD;
          -  Be healthy on the basis of clinical laboratory tests performed at screening. If the&#xD;
             results of the serum chemistry panel, hematology, or urinalysis are outside the normal&#xD;
             reference ranges, the participant may be included only if the investigator judges the&#xD;
             abnormalities or deviations from normal to be not clinically significant. This&#xD;
             determination must be recorded in the participant's source documents and initialed by&#xD;
             the investigator&#xD;
&#xD;
          -  Blood pressure (after the participant supine for 5 minutes) between 90 and 140&#xD;
             millimeter of Mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg&#xD;
             diastolic. If blood pressure is out of range, up to 2 repeated assessments are&#xD;
             permitted&#xD;
&#xD;
          -  During the study and for a minimum of 1 spermatogenesis cycle (defined as&#xD;
             approximately 90 days) after receiving the last dose of study intervention, a&#xD;
             participant must wear a condom when engaging in any activity that allows for passage&#xD;
             of ejaculate to another person. Male participants should also be advised of the&#xD;
             benefit for a female partner to use a highly effective method of contraception as&#xD;
             condom may break or leak. Recommended highly effective methods of contraception in&#xD;
             this study for female partners of male participants to use in addition to the male&#xD;
             participant wearing a condom during include: a) oral hormonal contraception, b)&#xD;
             intrauterine device, c) intrauterine hormone-releasing system, and d) bilateral tubal&#xD;
             occlusion&#xD;
&#xD;
          -  A participant must agree not to donate sperm for the purpose of reproduction during&#xD;
             the study and for a minimum 90 days after receiving the last dose of study&#xD;
             intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or current clinically significant medical illness including (but not&#xD;
             limited to) cardiac arrhythmias or other cardiac disease, hematologic disease,&#xD;
             coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid&#xD;
             abnormalities, significant pulmonary disease, including bronchospastic respiratory&#xD;
             disease, diabetes mellitus, hepatic or renal insufficiency, thyroid disease,&#xD;
             neurologic or psychiatric disease, infection or any other illness that the&#xD;
             investigator considers should exclude the participant or that could interfere with the&#xD;
             interpretation of the study results&#xD;
&#xD;
          -  Clinically significant abnormal values for hematology, clinical chemistry, or&#xD;
             urinalysis at screening as deemed appropriate by the investigator&#xD;
&#xD;
          -  Clinically significant abnormal physical examination, vital signs, or 12 lead&#xD;
             electrocardiogram (ECG) at screening as deemed appropriate by the investigator&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to JNJ-40411813 or its excipients&#xD;
&#xD;
          -  Test positive for human immunodeficiency virus (HIV) antigen/antibodies, hepatitis A&#xD;
             antibody immunoglobulin M (IgM), syphilis, hepatitis B surface antigen (HbsAg) or&#xD;
             hepatitis C virus (HCV) antibodies at screening&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K., Japan Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Souseikai Fukuoka Mirai Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108942</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinicaltrials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

